ArticleAmerican journal of public health2021
The Societal Value of Vaccination in the Age of COVID-19.
Article in American journal of public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.Journal of neurology · 2022Trial
- Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- The impacts of COVID-19 on routine immunization for children in Rwanda.BMC infectious diseases · 2026Article
- Vaccine spending and economic recovery: OECD panel data analysis.Northern clinics of Istanbul · 2026Article
- Retrospective Cohort Analysis of Survival After SARS-CoV-2 Infection by Vaccination Status in Jamaica, April-December 2021.Vaccines · 2025Article
- Article
- Article
- The macroeconomic impact of a dengue outbreak: Case studies from Thailand and Brazil.PLoS neglected tropical diseases · 2024Article
- The COVID-19 Vaccine Hesitancy Among Healthcare Workers: An Exploration of Hesitancy Reasons and Suggestions to Improve Vaccination Rates.Infectious diseases & clinical microbiology · 2024Article
- Identifying characteristics that enable resilient immunisation programmes: a scoping review.BMJ open · 2024Article
- Causes and costs of global COVID-19 vaccine inequity.Seminars in immunopathology · 2024Review
- Self-reported side effects of COVID-19 vaccines among the public.Journal of pharmaceutical policy and practice · 2024Article
- Is vaccine hesitancy related to mental health after the adjustment of the zero-COVID-19 strategy in the elderly? A mediation analysis in China.Human vaccines & immunotherapeutics · 2023Article
- Meningococcal Disease in the Post-COVID-19 Era: A Time to Prepare.Infectious diseases and therapy · 2023Article
- The full health, economic, and social benefits of prospective Strep A vaccination.NPJ vaccines · 2023Article
- The barriers, facilitators and association of vaccine certificates on COVID-19 vaccine uptake: a scoping review.Globalization and health · 2023Article
- The patient perspective on vaccine uptake in adults with psoriasis and eczema.Archives of dermatological research · 2023Article
- Protection against Severe Illness versus Immunity-Redefining Vaccine Effectiveness in the Aftermath of COVID-19.Microorganisms · 2023Review
- Modes of COVID-19 Information and Vaccine Hesitancy Among Asian Americans: The Moderating Role of Exposure to Cyberbullying.AJPM focus · 2023Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, academics and policymakers have increasingly recognized that the full societal value of vaccination encompasses broad health, economic, and social benefits beyond avoided morbidity and mortality due to infection by the targeted pathogen and limited health care costs. Nevertheless, standard economic evaluations of vaccines continue to focus on a relatively narrow set of health-centric benefits, with consequences for vaccination policies and public investments.The COVID-19 pandemic illustrates in stark terms the multiplicity and magnitude of harms that infectious diseases may inflict on society. COVID-19 has overtaxed health systems, disrupted routine immunization programs, forced school and workplace closures, impeded the operation of international supply chains, suppressed aggregate demand, and exacerbated existing social inequities.The obvious nature of the pandemic's broad effects could conceivably convince more policymakers to identify and account for the full societal impacts of infectious disease when evaluating the potential benefits of vaccination. Such a shift could make a big difference in how we allocate societal resources in the service of population health and in how much we stand to gain from that spending.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.